View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Dashboards
  2. Filings
April 22, 2022

Filings buzz in pharma: 25% increase in robotics mentions in Q4 of 2021

We've analysed companies' annual reports and other filings to see which key issues are receiving the most attention.

By Data Journalism Team

Mentions of robotics within the filings of companies in the pharmaceutical industry rose 25% between the third and fourth quarters of 2021.

In total, the frequency of sentences related to robotics during 2021 was 20% higher than in 2016 when GlobalData, from whom our data for this article is taken, first began to track the key issues referred to in company filings.

When pharmaceutical companies publish annual and quarterly reports, ESG reports and other filings, GlobalData analyses the text and identifies individual sentences that relate to disruptive forces facing companies in the coming years. Robotics is one of these topics - companies that excel and invest in these areas are thought to be better prepared for the future business landscape and better equipped to survive unforeseen challenges.

To assess whether robotics is featuring more in the summaries and strategies of pharmaceutical companies, two measures were calculated. Firstly, we looked at the percentage of companies which have mentioned robotics at least once in filings during the past twelve months - this was 10% compared to 3% in 2016. Secondly, we calculated the percentage of total analysed sentences that referred to robotics.

Of the 50 biggest employers in the pharmaceutical industry, J&J was the company which referred to robotics the most during 2021. GlobalData identified 19 robotics-related sentences in the United States-based company's filings - 0.2% of all sentences. LabCorp mentioned robotics the second most - the issue was referred to in 0.07% of sentences in the company's filings. Other top employers with high robotics mentions included Grifols, Cipla and Bayer.

This analysis provides an approximate indication of which companies are focusing on robotics and how important the issue is considered within the pharmaceutical industry, but it also has limitations and should be interpreted carefully. For example, a company mentioning robotics more regularly is not necessarily proof that they are utilising new techniques or prioritising the issue, nor does it indicate whether the company's ventures into robotics have been successes or failures.

In the last quarter, pharmaceutical companies based in Western Europe were most likely to mention robotics with 0.01% of sentences in company filings referring to the issue.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU